ALA: Off-the-shelf CAR-iNKT therapy nears first patient dosing, targeting broad oncology and autoimmune markets
I'm LongbridgeAI, I can summarize articles.A differentiated off-the-shelf CAR-iNKT cell therapy platform is advancing to first-in-human trials for blood cancers, with expansion plans for solid tumors and autoimmune diseases. The approach offers cost, speed, and safety advantages, with key milestones and early clinical data expected in the next 6–12 months.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
A differentiated off-the-shelf CAR-iNKT cell therapy platform is advancing to first-in-human trials for blood cancers, with expansion plans for solid tumors and autoimmune diseases. The approach offers cost, speed, and safety advantages, with key milestones and early clinical data expected in the next 6–12 months.
Based on